View allAllogeneic Cell SourcingCell Collection NetworkCell Therapy Supply ChainClinical Trials SupportIndustry StandardizationOutcomes ReportingSales Sheets
Sort by dateSort by name
DescendingAscending

UK Review and Recommendations on the Procurement of Starting Materials by Apheresis for ATMP Manufacture

Cell Collection Network, Cell Therapy Supply Chain, Industry Standardization

To ensure safe, high-quality Advanced Therapy Medicinal Products (ATMPs) are delivered to patients, procurement activities must be standardized when possible. Standardization also supports efficiency and reduces the risk for error while meeting regulatory and accreditation requirements. Download the UK Review and Recommendations on the Procurement of Starting Materials by Apheresis for ATMP Manufacture for insights…

The EBMT/EHA CAR-T Cell Handbook

Cell Collection Network, Cell Therapy Supply Chain, Industry Standardization

A joint venture between the European Society of Blood and Marrow Transplantation (EBMT) and the European Hematology Association (EHA), the CAR-T Cell Handbook offers clinical care applications for health care professionals in the EU that treat patients with CAR-T cell therapies. Download the guide for insights into many aspects of CAR-T cell therapies including: The…

Webinar

Streamlining Your Supply Chain to Support Next-Gen Therapies

Cell Therapy Supply Chain

As your cell and gene therapies move from early-phase clinical trials to commercialization, your supply chain complexity—and risk—increases. Anticipating setbacks and planning for their solution requires a specialized and collaborative approach with your supply chain partner. During this on-demand webinar, you’ll hear from industry experts who offer insights into developing a commercial supply chain for emerging autologous and allogeneic…

Webinar

Size Matters: Ensuring Donor Pool Sustainability and Cell Therapy Supply Chain Success When Scaling Up and Out

Allogeneic Cell Sourcing, Cell Therapy Supply Chain

View this on-demand webinar to learn how to increase potential for long-term success and ensure donor pool sustainability in allogeneic and autologous programs. Discover the keys to enabling a smoother, faster transition to market and ultimately, access to more patients. Our expert panelists will cover: What to expect when transitioning from small trial sizes to…

Webinar

Scaling Up and Out: Developing a Commercial Supply Chain Strategy to Successfully Deliver Next-Generation Therapies

Cell Therapy Supply Chain

With the introduction of innovative cell and gene therapies to market, scalable commercial supply chain strategies are critical to successfully delivering these therapies to patients. The delivery of cell and gene therapies depends on well-designed supply chains. Scaling your supply chain up to achieve this requires having, or finding partners with, proven experience in navigating…

Webinar

No Room for Error: Preparing for Inevitable Variability in the Cell and Gene Therapy Supply Chain

Cell Therapy Supply Chain

Orchestrating cell and gene therapy logistics is complex and susceptible to variability at each point of the supply chain. When shipments are life-critical, delays and oversights can be fatal. As operations scale from small populations in early-phase clinical trials to larger populations in late-stage trials and commercial launch, your supply chain complexity and risk increases.…

BioTherapies White Paper

How to Overcome 3 Common Cell Therapy Supply Chain Disruptions

Cell Therapy Supply Chain, Industry Standardization

The successful on-time delivery of cell and gene therapies isn’t just good business—it’s a matter of survival for patients. When there’s no room for mistakes, you need an advanced approach to overcome barriers to on-time delivery. In our more than 30 years of experience managing the collection and delivery for time-sensitive cell therapies around the…

Webinar

From Clinic to Commercial Reality: Leveraging Transplant Experience to Overcome Cell Therapy Supply Chain Hurdles

Cell Therapy Supply Chain

View this on-demand presentation of From Clinic to Commercial Reality by our Director of Cell and Gene Therapy Operations, Jamie Margolis, PhD, and our Vice President of Business Development and Strategic Partnerships, Mark Flower, to learn more about how NMDP BioTherapies (formerly Be The Match BioTherapies) is going beyond hematopoietic cell transplant and leveraging 30+…

BioTherapies White Paper

6 Considerations When Evaluating Cell Sourcing Partners

Allogeneic Cell Sourcing, Cell Collection Network, Cell Therapy Supply Chain

Sourcing your starting material from healthy, high-quality donors matters when you are manufacturing an allogeneic cell therapy. Any misstep can mean delays in your therapy’s development. Keep these key considerations top of mind as you evaluate whether potential partners have the experience, expertise and relationships required to identify, source and collect your allogeneic donors and…